arrow_back
Medical Information
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2024 Gilead Sciences, Inc. All rights reserved. IHQ-UNB-5659 May 2024

Thoracic research.

Lung cancer is the second most common cancer with 2.2M annual new lung cancer diagnoses globally¹, and is the leading cause of cancer death with 1.8M annual deaths². Up to 85% of lung cancers are NSCLC and 10-15% are SCLC. NSCLC tends to grow and spread slower than SCLC, but is still an aggressive disease with poor prognosis, with major unmet need for patients.

Research commitment
Clinical trials in progress
Scientific focus

Committed to patients living with Thoracic cancer

Select a trial below to view additional details (trial brochure or clinicaltrials.gov)
Timeline is based on trial start dates.
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

2019
TROPiCS-03a,*

2L+ mNSCLC, mHNSCC, mSCLC cohorts

2020
ARC-7a,b,*

1L mNSCLC

2021
EVOKE-01c

2-3L mNSCLC

2022
EVOKE-02a,d,*

1L mNSCLC

 
STAR-121b,*

1L mNSCLC

2023
EDGE-Lungb,*

1-2L mNSCLC

 
EVOKE-03d,*

1L mNSCLC, PD-L1+, TPS≥50%

 
VELOCITY-Lungb,*

Stage 2-3 resectable NSCLC, 1-2L mNSCLC

00

Clinical trials in progress

Thoracic clinical trials actively recruiting.

Rollover trial for links to trial brochures and/or clinicaltrials.gov records.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

1L mNSCLC, PD-L1+, TPS≥50%
Phase 3 randomized, open-label, multicenter, comparator-controlled clinical study of pembrolizumab in combination with sacituzumab govitecan versus pembrolizumab monotherapy as first-line treatment in patients with PD-L1 TPS ≥50% mNSCLC
NSCLC

EVOKE-03d

1L mNSCLC
Phase 3 randomized, open-label study to evaluate zimberelimab and domvanalimab in combination with chemotherapy versus pembrolizumab with chemotherapy for the 1L treatment of patients with metastatic NSCLC with no EGFR or ALK genomic tumor aberrations
NSCLC

STAR-121b

1-2L mNSCLC
Phase 2, open-label, platform study, to evaluate immunotherapy-based combinations in participants with advanced NSCLC
NSCLC

EDGE-Lungb

Stage 2-3 resectable NSCLC, 1-2L mNSCLC
Phase 2 platform study evaluating the safety and efficacy of novel treatment combinations in patients with lung cancer
NSCLC

VELOCITY-Lungb

Scientific focus

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

MoAs in research

sacituzumab govitecan-hziy
dom and zim
etruma and quemli

Clinicaltrials.gov may not reflect the most up-to-date information on the trials shown.

*Ongoing trials

aTrial status: active, not recruiting. bIn collaboration with Arcus Biosciences cStudy stopped enrollment and discontinued.dIn collaboration with Merck.

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FL, follicular lymphoma; HNSCC, head and neck squamous cell carcinoma; mNSCLC, metastatic non-small cell lung cancer; mSCLC, metastatic small cell lung cancer; NCT, national clinical trial; NSCLC, non-small cell lung cancer; PD-L1, programd death-ligand 1; R/R, relapsed/refractory; SCLC, small cell lung cancer; TPS, tumor proportion score.

1. Sung H et al. CA Cancer J Clin. 2021;71:209-249. 2. NCI SEER Cancer Stat Facts: Lung and Bronchus Cancer. Accessed May 30, 2023. https://seer.cancer.gov/statfacts/html/lungb.html